Summary
This computational study interrogated the paradoxical relationship between high immune infiltration in bladder cancer and poor response to immune checkpoint inhibitors. Using gene expression analysis linked to clinical trial data, the authors identified five genes whose elevated expression correlated with reduced IMCI efficacy, suggesting that baseline immune microenvironment composition may be a negative predictor of checkpoint inhibitor benefit.
UK applicability
This finding is directly applicable to UK oncology practice, where immune checkpoint inhibitors are routinely used for advanced bladder cancer. The identified gene signatures could inform treatment selection and patient stratification in NHS urological oncology services.
Key measures
Immune cell infiltration levels (estimated by single-sample gene set enrichment analysis); response rates to programmed cell death ligand-1 inhibitors from IMvigor 210 trial; expression levels of five predictive genes
Outcomes reported
The study examined the relationship between immune cell infiltration levels (ICILs) and response rates to immune checkpoint inhibitors (IMCIs) in bladder urothelial cancer patients. Five key genes were identified that could predict ICILs and potentially forecast reduced IMCI treatment response.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.